The shareholder vote removes the last major regulatory/approval hurdle for the AbbVie acquisition. The deal is now subject to remaining antitrust clearances (Australia ACCC) and customary closing conditions. Traders should monitor for the final regulatory sign-offs and the expected closing date; the stock should trade near the $135.11 offer price minus any remaining risk premium.
APGE drugs
APGE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 12 $134.55entry
- T+1 · 3mo ago −0.07%α −0.77% · $134.45
- T+5 · 3mo ago +0.12%α +0.56% · $134.71
- T+20 · due 2mo ago Pending
- T+60 · due 12d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisition by AbbVie, with 46,508,107 votes for and only 3,885 against, satisfying a key closing condition. The board also disclosed that all seven directors intend to resign effective at the merger's closing, a routine step in a change-of-control transaction. The non-binding advisory vote on executive merger-related compensation was rejected, but this does not affect deal consummation. The merger remains on track with German antitrust clearance already obtained and an Australian filing underway.
Key Facts
- Stockholders approved the merger proposal with 46,508,107 votes for, 3,885 against, and 14,261 abstentions.
- All seven directors (Michael Henderson, Mark C. McKenna, Lisa Bollinger, Jennifer Fox, William (BJ) Jones, Jr., Tomas Kiselak, Nimish Shah) intend to resign effective at the merger closing.
- The non-binding advisory vote on executive merger compensation was not approved (19,323,605 for, 27,123,259 against), but this is not a condition to closing.
- The merger is an all-cash acquisition by AbbVie at $135.11 per share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.
- German antitrust clearance (FCO) was obtained on July 27, 2026, and an Australian ACCC filing is underway.
Financial Impact
All-cash acquisition at $135.11/share, valuing Apogee at approximately $8.4B based on 62,140,183 voting shares outstanding.
Risk Factors
- Remaining antitrust clearances (Australia ACCC) could delay closing.
- The non-binding compensation vote rejection signals potential shareholder dissent, though it does not block the deal.
- Any unexpected regulatory or litigation developments could delay or derail the merger.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032231 |
| Document: 0001140361-26-032231-index-headers.html | 0001140361-26-032231 |
| Document: 0001140361-26-032231-index.html | 0001140361-26-032231 |
| Document: 0001140361-26-032231.txt | 0001140361-26-032231 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Viewing Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers